More people enrolling in health insurance, that likely means more prescriptions and ultimately more profits for pharmaceuticals. More
- ADVERTISEMENT
-
- Poll of the Day
- Partners
- ADVERTISEMENT
BMY
Recent Articles
Why Bristol-Myers Squibb is a Top 25 Dividend Giant (BMY)
Bristol-Myers Squibb has been named as a Top 25 Dividend Giant by ETF Channel, with a staggering $3.09B worth of stock held by ETFs. More
5 Biotech Stocks Promising Future Rewards
Biotech is one of the dynamic sectors in our economy, and in the stock market as well. These 5 biotech stocks are solid buys in our Portfolio Grader model. More
MRK: Merck Stock a Strong Performer In the Pharma Space
Merck is one the most high profile companies in the pharmaceutical industry, and Merck stock is well worth a look for investors. I rate it a buy today. More
BMY Pummeled After Earnings, But Bristol-Myers Squibb Stock Still a Buy
Bristol-Myers Squibb stock has a lot going for it, like the company's newfound focus on hepatitis C, oncology and immunotherapy. But BMY still might need time to reflect that potential. More
Farxiga: FDA Approves New Drug for Type 2 Diabetes
The FDA has approved a Type 2 Diabetes drug called Farxiga. However, the FDA is ordering post-approval studies to learn more about the drug's side effects. More
5 Pharmaceutical Stocks to Buy Now
Five pharmaceutical stocks are moving up in their overall rating this week, according to the Portfolio Grader database. Every one of these is graded an "A" ("strong buy") or "B" overall ("buy"). More
